Vision Research Center
Created through the transformational philanthropy of Vickie and Jack Farber, the Vickie and Jack Farber Vision Research Center (VRC) at Wills Eye Hospital demonstrates a commitment to excellence in vision research aimed to impact sight preservation and eye health for generations to come.
Our mission is to leverage clinical and technological advances in health delivery systems, data analytics, artificial intelligence, genetics and precision medicine to drive breakthroughs through collaboration and innovation that empower lives by preserving vision through preventing, treating and curing eye disease. Learn more.
Wills Eye is harnessing the power and possibility of technology to transform data and information into knowledge that can improve patient outcomes and advance the delivery of eye care.
An international team of thought leaders with a wide range of expertise in and outside ophthalmology examine new pathways and potentially transformational technology to advance eyecare and fight vision loss.
Glaucoma research at Wills Eye includes pharmacologic advancements in the treatment of glaucoma and surgical interventions to minimize risk and improve outcomes of glaucoma surgery, including the use of new and novel surgical devices.
Diabetic retinopathy, a complication of diabetes, affects the eyes by causing deterioration of blood vessels in the retina. Wills Eye retina doctors are leading experts in the treatment of diabetic retinopathy with the latest clinical trials and new therapeutic approaches for this disease.
Macular degeneration refers to the age-related degenerative changes in the retina that can result in loss of central vision. Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple clinical trials to investigate new and emerging forms of treatment for AMD.
Graft Outcomes After Temporary Keratoprosthesis in Combined Penetrating Keratoplasty and Vitreoretinal Surgery
Yu J, Shalaby WS, Shiuey EJ, Rapuano CJ, Yonekawa Y, Hammersmith KM, Nagra PK, Syed ZA.
Corneal pathology can obstruct the visualization required for surgical management of coexisting posterior segment diseases, and use of a temporary keratoprosthesis (TKP) permits combined penetrating keratoplasty (PK) and vitreoretinal surgery. The researchers evaluated graft outcomes after TKP for combined PK and vitreoretinal surgery and analyzed risk factors for graft failure.
Wills Eye research aims to leverage clinical and technological advances to drive breakthroughs in eye care. We are inventing the standards of tomorrow and training the next generation of clinician scientists. The only way we can fully realize our potential is with the support of our courageous patients and philanthropists, the people who have the foresight to understand these challenges. With your gift, you make an investment in leading-edge research that advances understanding and enhances life for generations to come.
"Wills Eye is a great institution with incredibly talented people who are motivated, forward thinking and committed to advancing scientific knowledge. If you put those energies together with financial support to accelerate the rate of progress, you truly make a difference in patients' lives."